Ashleigh Palmer

AMGN, Arthritis, Ashleigh Palmer, autoimmune diseases, Benzinga, Biotech, celiac disease, Diabetes, Exclusives, General, Interview, Janssen, JNJ, multiple sclerosis, PRVB, rheumatoid arthritis, teplizumab, Top stories, Type 1 diabetes, US0311621009, US4781601046

Provention Bio’s CEO On Identifying Autoimmune Diseases ‘Before It’s Too Late’

When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention.
read more